Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4467000
Max Phase: Preclinical
Molecular Formula: C17H17N3O2S
Molecular Weight: 327.41
Molecule Type: Unknown
Associated Items:
ID: ALA4467000
Max Phase: Preclinical
Molecular Formula: C17H17N3O2S
Molecular Weight: 327.41
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC(C)c1ccc(Oc2ccnc3sc(C(N)=O)c(N)c23)cc1
Standard InChI: InChI=1S/C17H17N3O2S/c1-9(2)10-3-5-11(6-4-10)22-12-7-8-20-17-13(12)14(18)15(23-17)16(19)21/h3-9H,18H2,1-2H3,(H2,19,21)
Standard InChI Key: YUWBWVLAHVEPML-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 327.41 | Molecular Weight (Monoisotopic): 327.1041 | AlogP: 3.89 | #Rotatable Bonds: 4 |
Polar Surface Area: 91.23 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 2 |
#RO5 Violations: 0 | HBA (Lipinski): 5 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: 0.84 | CX LogP: 3.55 | CX LogD: 3.55 |
Aromatic Rings: 3 | Heavy Atoms: 23 | QED Weighted: 0.76 | Np Likeness Score: -1.15 |
1. Saito K, Shinozuka T, Nakao A, Kiho T, Kunikata T, Shiiki T, Nagai Y, Naito S.. (2019) Synthesis and structure-activity relationship of 4-alkoxy-thieno[2,3-b]pyridine derivatives as potent alkaline phosphatase enhancers for osteoporosis treatment., 29 (14): [PMID:31101474] [10.1016/j.bmcl.2019.05.014] |
Source(1):